Diassess Inc. (now Lucira Health Inc.) developed a compact rapid diagnostic tester of Flu and STDs. The original design provided a visual color change at the end of the test and was intended to be read out by a trained professional. Early trials demonstrated that it was difficult to create a definitive reading. Gener8 was asked to investigate if a low-cost electronic reader could be developed for either a disposable handheld device or for a higher throughput benchtop unit. The initial aim of this work was to investigate available technologies and propose solutions that could be implemented within a tight budget.
This test, originally developed for the Flu virus, later became the first FDA approved sample to result in-home test for Covid-19.